192 related articles for article (PubMed ID: 34472328)
1. Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19.
Yin Y; Su W; Zhang J; Huang W; Li X; Ma H; Tan M; Song H; Cao G; Yu S; Yu D; Jeong JH; Zhao X; Li H; Nie G; Wang H
ACS Nano; 2021 Sep; 15(9):14347-14359. PubMed ID: 34472328
[TBL] [Abstract][Full Text] [Related]
2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
3. Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants.
Fan F; Zhang X; Zhang Z; Ding Y; Wang L; Xu X; Pan Y; Gong FY; Jiang L; Kang L; Ha Z; Lu H; Hou J; Kou Z; Zhao G; Wang B; Gao XM
Emerg Microbes Infect; 2023 Dec; 12(1):2202269. PubMed ID: 37038652
[TBL] [Abstract][Full Text] [Related]
4. Microneedle technology for potential SARS-CoV-2 vaccine delivery.
McNamee M; Wong S; Guy O; Sharma S
Expert Opin Drug Deliv; 2023 Jun; 20(6):799-814. PubMed ID: 37128730
[TBL] [Abstract][Full Text] [Related]
5. Rapid Induction of Long-Lasting Systemic and Mucosal Immunity via Thermostable Microneedle-Mediated Chitosan Oligosaccharide-Encapsulated DNA Nanoparticles.
Li M; Yang L; Wang C; Cui M; Wen Z; Liao Z; Han Z; Zhao Y; Lang B; Chen H; Qian J; Shu Y; Zeng X; Sun C
ACS Nano; 2023 Dec; 17(23):24200-24217. PubMed ID: 37991848
[TBL] [Abstract][Full Text] [Related]
6. An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination.
Xia D; Jin R; Byagathvalli G; Yu H; Ye L; Lu CY; Bhamla MS; Yang C; Prausnitz MR
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34670842
[TBL] [Abstract][Full Text] [Related]
7. The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.
Kapnick SM
DNA Cell Biol; 2022 Jan; 41(1):25-29. PubMed ID: 34958232
[TBL] [Abstract][Full Text] [Related]
8. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
9. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines.
Vander Straeten A; Sarmadi M; Daristotle JL; Kanelli M; Tostanoski LH; Collins J; Pardeshi A; Han J; Varshney D; Eshaghi B; Garcia J; Forster TA; Li G; Menon N; Pyon SL; Zhang L; Jacob-Dolan C; Powers OC; Hall K; Alsaiari SK; Wolf M; Tibbitt MW; Farra R; Barouch DH; Langer R; Jaklenec A
Nat Biotechnol; 2024 Mar; 42(3):510-517. PubMed ID: 37095347
[TBL] [Abstract][Full Text] [Related]
10. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
Front Immunol; 2022; 13():908108. PubMed ID: 35911701
[TBL] [Abstract][Full Text] [Related]
11. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
12. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
[TBL] [Abstract][Full Text] [Related]
13. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
14. Smart Mushroom-Inspired Imprintable and Lightly Detachable (MILD) Microneedle Patterns for Effective COVID-19 Vaccination and Decentralized Information Storage.
Li Q; Xu R; Fan H; Xu J; Xu Y; Cao P; Zhang Y; Liang T; Zhang Y; Chen W; Wang Z; Wang L; Chen X
ACS Nano; 2022 May; 16(5):7512-7524. PubMed ID: 35451839
[TBL] [Abstract][Full Text] [Related]
15. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice.
Carey JB; Pearson FE; Vrdoljak A; McGrath MG; Crean AM; Walsh PT; Doody T; O'Mahony C; Hill AV; Moore AC
PLoS One; 2011; 6(7):e22442. PubMed ID: 21799855
[TBL] [Abstract][Full Text] [Related]
16. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
17. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
18. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
19. Rabies vaccination in dogs using a dissolving microneedle patch.
Arya JM; Dewitt K; Scott-Garrard M; Chiang YW; Prausnitz MR
J Control Release; 2016 Oct; 239():19-26. PubMed ID: 27524283
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
Yi X; Wang Y; Li Q; Li X; Zhang P; Fu X; Gu S; Zhang D; Liu X; Lou H; Wu Y; Tang L; Hou J; Li Y
J Med Virol; 2023 Mar; 95(3):e28642. PubMed ID: 36890630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
